Provided by Tiger Trade Technology Pte. Ltd.

Nektar Therapeutics

74.34
+2.122.94%
Post-market: 74.500.1600+0.22%16:58 EDT
Volume:699.85K
Turnover:51.46M
Market Cap:2.13B
PE:-7.64
High:74.48
Open:73.00
Low:71.94
Close:72.22
52wk High:77.00
52wk Low:6.48
Shares:28.69M
Float Shares:26.24M
Volume Ratio:1.00
T/O Rate:2.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-9.7300
EPS(LYR):-8.6765
ROE:-217.94%
ROA:-27.98%
PB:23.74
PE(LYR):-8.57

Loading ...

Nektar Therapeutics - Both Rezpegaldesleukin Treatment Arms Met Statistical Significance Excluding Violations

THOMSON REUTERS
·
Dec 16, 2025

Nektar Therapeutics - Rezolve-Aa Phase 2B Study Results Supports Advancement to Phase 3 Development in Alopecia Areata

THOMSON REUTERS
·
Dec 16, 2025

Nektar Therapeutics - Rezpegaldesleukin Well Tolerated With Consistent Safety Profile

THOMSON REUTERS
·
Dec 16, 2025

Nektar Therapeutics - Rezolve-Aa Phase 2B Study Achieved Target Product Profile With 28.2% Salt Score Reduction

THOMSON REUTERS
·
Dec 16, 2025

Nektar Study Establishes Proof-of-Concept in Patients with Severe Alopecia Areata

Dow Jones
·
Dec 16, 2025

Nektar Therapeutics Reports Positive Phase 2b Results for Rezpegaldesleukin in Alopecia Areata

Reuters
·
Dec 16, 2025

NASDAQ TRADE HALT HALT NEWS PENDING AT 07:25 AM

Reuters
·
Dec 16, 2025

Nektar Therapeutics Jumps Pre-Bell Ahead of Phase 2b Topline Results for Alopecia Areata Treatment

MT Newswires Live
·
Dec 16, 2025

Nektar to Hold Conference Call to Discuss Topline Results From the 36-Week Induction Treatment Period for Its Rezolve-Aa Phase 2B Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025

THOMSON REUTERS
·
Dec 16, 2025

Nektar Therapeutics Grants Stock Options to New Employees Under 2025 Inducement Plan

Reuters
·
Dec 06, 2025

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Dec 06, 2025

Nektar Therapeutics Is Maintained at Buy by Jefferies

Dow Jones
·
Nov 27, 2025

Nektar price target raised to $121 from $99 at Jefferies

TIPRANKS
·
Nov 26, 2025

Nektar Therapeutics President and CEO Howard W. Robin Reports Disposal of Common Shares

Reuters
·
Nov 26, 2025

How Investors May Respond To Nektar Therapeutics (NKTR) Clinical Progress and Leadership Transition

Simply Wall St.
·
Nov 25, 2025

Nektar Therapeutics Announces Chief Legal Officer Departure

TIPRANKS
·
Nov 22, 2025

Nektar Therapeutics Names Elizabeth Zhang as Chief Legal Officer

Reuters
·
Nov 22, 2025

Nektar Therapeutics Q3 EPS USD -1.87

Reuters
·
Nov 20, 2025

Nektar Therapeutics (NKTR): Assessing Valuation After $110 Million Equity Offering and New Shelf Registrations

Simply Wall St.
·
Nov 17, 2025

Nektar Therapeutics: Buy Rating Driven by Promising REZPEG Data and Favorable Safety Profile in Alopecia Areata Treatment

TIPRANKS
·
Nov 16, 2025